about
Pharmacotherapies for obesity: past, current, and future therapiesPsychological interventions for adults who are overweight or obesePsychosocial interventions for the maintenance of weight loss in obese adultsVitamin D supplementation for overweight or obese adultsPharmacological interventions for reducing weight gain in schizophreniaMetformin for obesity or overweightMetformin for obesity or overweightInterventions to reduce weight gain in schizophreniaPsychosocial interventions for the maintenance of weight loss in obese adultsAnti-Obesity Drugs: A Review about Their Effects and SafetyThe GLP-1 agonist, liraglutide, as a pharmacotherapy for obesityTherapy for obesity based on gastrointestinal hormonesDrug interventions for the treatment of obesity in children and adolescentsTackling obesity: new therapeutic agents for assisted weight loss.The impact of a bariatric rehabilitation service on weight loss and psychological adjustment--study protocolEmerging treatment options for type 2 diabetes2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.The cost-effectiveness and consumer acceptability of taxation strategies to reduce rates of overweight and obesity among children in Australia: study protocolBariatric Surgery can Lead to Net Cost Savings to Health Care Systems: Results from a Comprehensive European Decision Analytic Model.Brown adipose tissue: endocrine determinants of function and therapeutic manipulation as a novel treatment strategy for obesity.Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.Causes and consequences of obesity: epigenetics or hypokinesis?Weight loss is still an essential intervention in obesity and its complications: a reviewAdvances in the treatment of nonalcoholic fatty liver disease.Intestinal mucosal atrophy and adaptationNOX2 deficiency attenuates markers of adiposopathy and brain injury induced by high-fat diet.The Mechanism by Which Safflower Yellow Decreases Body Fat Mass and Improves Insulin Sensitivity in HFD-Induced Obese Mice.Current pharmacotherapeutic concepts for the treatment of obesity in adults.Obesity: its epidemiology, comorbidities, and managementMyeloid-specific deletion of NOX2 prevents the metabolic and neurologic consequences of high fat diet.The effect of (L-)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials.Orlistat-induced fulminant hepatic failure.Reversible serum carcinoembryogenic antigen (CEA) elevation due to orlistat use: A case report.The long-term management of obesity with continuing pharmacotherapy.Lipid targets in clinical practice: successes, failures and lessons to be learned.Euphorbia kansui Attenuates Insulin Resistance in Obese Human Subjects and High-Fat Diet-Induced Obese Mice.Meta-analysis and subgroups.
P2860
Q21296814-E5EA8DC4-54C3-4412-BD47-C218B086FB99Q24186064-7B71BBC3-EB01-4A20-935E-994E710FF992Q24186273-AB3779AD-A6DF-49E7-B840-0EFDEE459A07Q24186925-1EA5D75E-57EF-44BD-A5B9-0B52A7315BB7Q24194410-8D83D07A-1FBC-42AD-9313-50803EA6778AQ24195145-35815872-99AD-4960-AE98-D65C87B4A9FDQ24236796-6C3A42CB-A0A2-400B-AAA1-CEE7E56CD67AQ24243093-E471D165-6CF9-461B-88D2-8CF2978E5BEBQ24243565-9FCF86CE-EE9C-4FF1-8A5F-AEEFD784D420Q24630947-229EAE4F-D3ED-47D2-8D14-202986C18D8DQ26765609-6DF2E803-8378-4424-A347-8F42C00C14CDQ27006777-879268E0-6D24-4DCE-B86D-885BDE956A81Q28279770-98A161F7-99F1-48C4-99F7-C60F58592D82Q30401145-A4C877EA-8886-4C15-AC72-1819CC140D80Q34222980-F1E0C397-917B-4279-9B80-19C39E22F952Q34381281-D44E2B52-3667-47B2-AF46-0C9158EEC429Q34384547-39570364-6AB7-4F98-9922-8686A4AFBC18Q35065121-323E2655-97BC-4FB0-B1E1-E46AD6394D1CQ35907975-0B07D0D5-D6F7-4CF5-9404-FB9E999F11F3Q35943980-04FC735C-B21D-4F14-BC64-882C55649E8AQ36028436-8AC253EF-4799-45DB-AB19-23936A7F381EQ36079417-B51632A6-7D42-40D1-A0F1-C6922B55FBBBQ36090438-1E16CAC2-BB07-422B-8CB1-A149011F4635Q36329908-821EBC9A-2191-4E0D-B91B-FDD623A8DDBFQ36429803-0D81FE18-E6DE-4D7F-82CF-B03EB8A8DBAFQ36593089-A4785CB5-0DA3-452B-AD7F-D05DE60E4388Q36926418-3DBD6CB5-12D9-4087-B09D-B962E0305F2CQ37368688-64866854-C0CF-4448-A495-D76E38EE76F4Q37533814-DB4F0871-D600-4C9E-8097-5F8EAFD8CB44Q38644482-48B8E1A8-306B-46A4-9999-E61E23816552Q38874032-4891B6A9-1EF9-4187-B64C-16C24977E3B9Q42151566-F4C0B55F-D196-4CF9-A2CB-5E0DB0879A05Q42737296-D7DFD7E8-4FCB-43DC-9106-B379E01EB7E9Q45188954-51174B7E-1FFE-4AEB-B0C5-E89A860999D2Q45330889-70A795C4-DE4F-4F52-8F85-8F115F3BE730Q47137397-BA896ABD-C32A-4568-8E35-6B58DC5A9E47Q50866901-ED316B10-9D92-4F5C-B297-EFB98435FA28
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Long-term pharmacotherapy for obesity and overweight
@ast
Long-term pharmacotherapy for obesity and overweight
@en
Long-term pharmacotherapy for obesity and overweight
@en-gb
Long-term pharmacotherapy for obesity and overweight
@nl
type
label
Long-term pharmacotherapy for obesity and overweight
@ast
Long-term pharmacotherapy for obesity and overweight
@en
Long-term pharmacotherapy for obesity and overweight
@en-gb
Long-term pharmacotherapy for obesity and overweight
@nl
prefLabel
Long-term pharmacotherapy for obesity and overweight
@ast
Long-term pharmacotherapy for obesity and overweight
@en
Long-term pharmacotherapy for obesity and overweight
@en-gb
Long-term pharmacotherapy for obesity and overweight
@nl
P2093
P2860
P1476
Long-term pharmacotherapy for obesity and overweight
@en
P2093
Cintia Curioni
David CW Lau
Diana Rucker
Raj S Padwal
Stephanie K Li
P2860
P356
10.1002/14651858.CD004094.PUB2
P577
2003-10-20T00:00:00Z